ALX Oncology reports Phase 2 failures for CD47 drug combo with Keytrudanews2025-04-25T15:09:05+00:00April 25th, 2025|Endpoints News|
Caribou lays off 32% of staff, cuts lupus programnews2025-04-24T20:15:36+00:00April 24th, 2025|Endpoints News|
Sanofi Q1 earnings: Altuviiio closing in on blockbuster status, Dupixent sales surgenews2025-04-24T10:19:56+00:00April 24th, 2025|Endpoints News|
Ascletis posts puzzling Phase 1 update on obesity pillnews2025-04-23T11:12:13+00:00April 23rd, 2025|Endpoints News|
Akeso reports another Phase 3 win for PD-1xVEGF approach in lung cancernews2025-04-23T11:11:24+00:00April 23rd, 2025|Endpoints News|
Boehringer taps Tessellate Bio for ALT positive cancer pact exceeding $573M in biobucksnews2025-04-23T07:00:12+00:00April 23rd, 2025|Endpoints News|
Bristol Myers’ schizophrenia drug fails Phase 3 trial for adjunctive treatmentnews2025-04-22T21:17:29+00:00April 22nd, 2025|Endpoints News|
AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu’s early Phase 3 winnews2025-04-22T10:16:36+00:00April 22nd, 2025|Endpoints News|
China biotech startup HuidaGene uses CRISPR in brain for rare ailmentnews2025-04-21T15:00:57+00:00April 21st, 2025|Endpoints News|
Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer studynews2025-04-21T13:24:55+00:00April 21st, 2025|Endpoints News|
